Stem cell research may hold key to restoring neural function in glaucoma patients

Article

At this time there is no therapy that can restore vision after retinal ganglion cell (RGC) death in patients with glaucoma. However, stem cell-based treatments do have the potential to restore function in individuals with various neurodegenerative diseases, reported Keith R. Martin, MD, of Cambridge University, Cambridge, England, at the annual meeting of the Association for Research in Vision and Ophthalmology.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Subscribe Now!
Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
Solid Biosciences' CPVT Gene Therapy SGT-501 Cleared for Phase 1b Trial

Solid Biosciences' CPVT Gene Therapy SGT-501 Cleared for Phase 1b Trial

Noah Stansfield
July 10th 2025
Article

SGT-501 is intended to address CPVT by providing a full-length, codon-optimized copy of the cardiac calsequestrin gene to the muscle cells of the heart.

Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center

Cell Therapy in Parkinson Disease: Bemdaneprocel and What Lies Ahead

Rajesh Pahwa, MD;Marco Meglio
June 18th 2025
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Rajesh Pahwa, MD.

Around the Helix: Cell and Gene Therapy Company Updates – July 9, 2025

Around the Helix: Cell and Gene Therapy Company Updates – July 9, 2025

Noah Stansfield
July 9th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

ProKidney’s Diabetes and CKD Cell Therapy Rilparencel Improves eGFR Slope Annual Decline in Phase 2 Trial

ProKidney’s Diabetes and CKD Cell Therapy Rilparencel Improves eGFR Slope Annual Decline in Phase 2 Trial

Noah Stansfield
July 8th 2025
Article

Alongside the new data from REGEN-007, ProKidney also announced that it will be attending a Type B meeting with the FDA later in the summer.

SineuGene Garners Orphan Drug Designation for ALS Gene Therapy

SineuGene Garners Orphan Drug Designation for ALS Gene Therapy

Noah Stansfield
July 7th 2025
Article

SNUG01 is intended to deliver a copy of the human TRIM72 gene to neurons via an rAAV9 vector.

© 2025 MJH Life Sciences

All rights reserved.